Novo accepts fine in Tresiba case
Novo Nordisk has decided to accept the fine the company was given by the Danish State Attorney in a case raised by the Danish FSA in connection with US approval agency FDA’s rejection of diabetes drug Tresiba.
BY STEFAN SINGH KAILAY
A court case in which Novo Nordisk’s management has been accused of delaying information about the US Food and Drug Administration’s rejection of diabetes drug Tresiba seems to have come to an end.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
